365Telugu.com online news,Mumbai, India & Princeton, N.J., July 15th, 2025:Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA, BSE: 524715), along with its subsidiaries and affiliates, has announced a settlement and license agreement with Incyte Corporation related to ongoing litigation concerning LEQSELVI™ (deuruxolitinib) in the United States.
This agreement follows Sun Pharma’s earlier disclosure dated April 10, 2025. As per the terms, both companies will jointly seek dismissal of the pending litigation in the U.S. District Court for the District of New Jersey, and will release each other from all claims raised—or that could have been raised—in the dispute.
As part of the settlement:
- Incyte will grant Sun Pharma a limited, non-exclusive license to U.S. Patent No. 9,662,335 and other related patents.
- The license pertains to oral deuruxolitinib for select non-hematology-oncology indications, including alopecia areata, within the United States.
- In exchange, Sun Pharma will make an upfront payment to Incyte, followed by ongoing royalty payments until the related patents expire.
The financial terms of the agreement remain confidential.
This resolution enables Sun Pharma to move forward with its U.S. development and commercialization plans for deuruxolitinib in approved indications, while avoiding prolonged litigation.
